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ABSTRACT  
Background: Uremia leads to a number of metabolic and hormonal disorders including 
defective carbohydrate metabolism. Endocannabinoids exert their effect on insulin and 
glucagon secretion via activation of specific receptors named CB1 and CB2. For this 
reason and the absence of reports on location and immunoreactivity of CB1, CB2 receptors 
compared to immunoreactivity of insulin- and glucagon- secreting cells in experimental 
uremia, the author decided to investigate this issue. The aim of the present study was the 
immunohistochemical localization and evaluation of cannabinoid receptors (CB1, CB2), 
insulin and glucagon in the pancreatic islets of uremic rats.  
Materials and methods: Fragments of the rats pancreas were collected 28 days after 
surgical resection of one kidney and removal of 70% of the other kidney cortex. Paraffin-
embedded sections were stained with H+E and immunohistochemical reactions were 
performed with the use of a specific antibody against CB1-, CB2- receptors, insulin and 
glucagon.  
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Results: It was revealed the decreased immunoreactivity of the CB1 receptor and higher 
intensity of the immunohistochemical reaction against CB2 receptor as compared to the 
value in the control animals. Significantly higher immunoreactivity of glucagon-positive 
cells and weaker immunoreactivity of insulin-positive cells were observed in pancreatic 
islets of uremic rats.  
Conclusions: The obtained results indicate the involvement of cannabinoid receptors in 
the pathomechanism of carbohydrate metabolism disorders, associated with abnormal 
secretion of hormones by the α and β cells in uremia. 
Key words: pancreatic islets, cannabinoid receptor, uremia, rat 
 
 
Introduction 
It is well known that chronic renal failure results in disorders of many organs and 
systems including carbohydrate metabolism [2, 3, 15]. Recent studies indicate a close 
functional relationship between the endocannabinoid system and hormones related to 
maintaining the energy and metabolic balance [18, 23, 30, 33].  
Due to the presence of CB1 and CB2 receptors in pancreatic islet cells, 
endocannabinoids are involved in the regulation of insulin and glucagon [1, 5, 6, 22, 35]. 
Several reports indicate that using CB1 receptor antagonist results in impaired insulin 
secretion and administration of an agonist leads to increased insulin secretion in rats [11, 
13, 22]. Similar observations have been made on patients treated with a CB1 receptor 
agonist [7]. Other studies on mice have shown a decrease in insulin secretion following  
CB1 receptor activation [28].  
It has been proven in experimental conditions that following the use of 
streptozotocin, β cell survival increases in animals with a pharmacological blockade or a 
genetic deficiency in the CB1 receptor. The same experiment revealed that the activation 
of this receptor induces the death of β cells in an insulin receptor–dependent manner [19]. 
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Recent reports indicate the presence of autonomous endocannabinoid system in the 
endocrine pancreas and emphasize important role of CB1 receptors in β –cells. In addition, 
the participation of α pancreatic islet cells in the synthesis of endocannabinoids and β cells 
in the synthesis of enzymes degrading endocannabinoids has been demonstrated [7, 25, 
26]. Activation of CB1 receptors by cannabinoids produced in α cells may lead to an 
increase in insulin secretion in β cells [25]. 
Endocannabinoids are synthesized on demand from derivatives of arachidonic acid 
bounded to membrane. After action, the endocannabinoids are rapidly degraded by specific 
enzymes and products are recycled. CB1 and CB2 are G-protein coupled receptors and 
inhibit activation of adenyl cyclase (AC) and cAMP-PKA activity as well as activate 
MAPK. In addition, CB1 receptor inhibits voltage- gated L- N- and P/Q- type Ca2+ 
channels and inwardly correcting K+ channels [14]. 
There are many pathways activated by the CB1 and CB2 receptors associated with 
the secretion and survival of pancreatic islet cells. CB1 receptor may induce activation of 
an inwardly rectifying K+ channel, resulting in decrease excitability and inhibition of 
voltage gated calcium channel and inhibition of Ca2+ influx. Activated CB1 or CB2 
receptor leads to the activation of p38 and p42/44 mitogen activated protein kinases 
(MAPKs). The P38 isoforms of MAPK can activate caspases and induce apoptosis, on the 
other hand  p42/p44 stimulates cellular proliferation. Gi/o activation evoked by CB1 and 
CB2 receptors indicate adenylate cyclase(AC) inhibition and subsequent reductions in 
cyclic AMP (cAMP). Under certain circumstances CB1 receptors may increases Ca2+ 
influx induced by stimulation AC via Gs and the increased cyclic AMP, then it can 
activates protein kinase A and result in phosphorylation of VGCCs.  Calcium level may be 
elevated also by activation of phospholipase C (PLC) via another pathway related with 
CB1 receptor.  Entry into this pathway may also result in stimulation of cellular 
proliferation [23].  
It is well known that renal failure leads to the accumulation of many toxic 
substances such as urea or reactive oxygen species which can impair the function and 
impact on the survival of a number of cell types inducing their apoptosis [20, 29, 34]. 
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In the current literature there is a lack of reports concerning cannabinoid receptors 
in the pancreatic islet area in uremia. 
The aim of the study was the immunohistochemical localisation of CB1, CB2 
cannabinoid receptors and insulin-, glucagon-secreting cells in the pancreas of uremic rats. 
 
Materials and methods 
Experimental animals 
The study was performed on 15 young male Wistar rats, their body weight at the 
beginning of the experiment within 200-220 g (the mean body weight: 210 ± 10g). The 
animals were kept in lighted and ventilated conditions with room temperature and 
maintained day and night rhythm. The animals had a free access to standard granulated 
chow and drinking water was available. All the experiments were performed at the same 
time of the day. Procedures involving the animals and their care were conducted in 
conformity with the institutional guidelines that were in compliance with national and 
international law and with guidelines for the use of animals in biomedical research. The 
experimental rats were divided into two groups: SH – five animals underwent a sham 
operation and experimental uremic group U –ten rats with experimentally induced uremia 
according to the method described by Ormord and Miller: surgical resection of one kidney 
and removal of 70% of the other kidney cortex. 
 
Method of experimental material collection and fixation 
After four weeks from the surgery, the rats were anesthetized by pentobarbital, 
administered interperitoneally (i.p.) at a dose of 50 mg/kg and blood was collected from 
their hearts. Then, the animals were sacrificed by decapitation. The pancreas was 
immediately removed. For microscopic analysis segments of the pancreatic distal parts 
were used, fixed in Bouin’s fluid and embedded in paraffin in the routine way. The 
specimens were cut into 4µm slices (Leica 2025 Autocut) and stained by hematoxylin-
eosin (H+E) for general histological examination.  
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Determination of urea and creatinine levels in blood serum 
Blood was collected from the heart for coagulation. Collected blood samples were 
left for twenty (20) minutes in room temperature to coagulate. Then, the cylinders with 
coagulated blood were centrifuged at 3000 RPM for fifteen (15) minutes. In the blood 
serum obtained, urea and creatinine levels were measured in a Backman-CX4 Analyser, 
using an "Urée cinetique UV 800" of BioMérieux.  
 
Immunohistochemical procedure 
An immunohistochemical reactions against CB1, CB2, insulin, glucagon were 
performed on 4 µm paraffin sections, obtained from the pancreas of the studied animals. 
Briefly: Sections were deparaffined and hydrated with pure ethanol In the 
immunohistochemical study, the EnVision method was used according to Herman and 
Elfont [16]. Antigen retrieval is recommended before commencing IHC staining: for 
glucagon is Target Retrieval Solution (S1700; Dako, Dennmark), and for CB-1 and CB-2 
is Target Retrieval Solution pH=9,0 (S2367; Dako, Dennmark). Tissues were blocked in 
Peroxidase Blocking Reagent (S 2001 Dako Denmark A/S, Produktionsvej 42, DK-2600 
Glostrup) for 10 minutes at room temperature. Sections were incubated in humified 
chamber with dilution primary antibodies: Insulin 1: 100 (A0564 Dako) and Glucagon 1: 
200 (A0565 Dako) (30 minutes RT); CB-1 (ab23703 ABCAM)  1 : 200 and CB-2 (ab3561 
ABCAM) 1: 2000 (24 hours in +4ºC). HRP polymer KIT (EnVision (+) HRP polymer 
anti-rabbit K 4011 Dako Denmark A/S, Produktionsvej 42, DK-2600 Glostrup) was used 
as the secondary antibody followed by colorimetric detection using chromogen DAB. 
Sections were counterstained with hematoxylin QS (Vector) and dehydrated with pure 
ethanol and xylene to prepare for mounting.  
 
Quantitative analysis 
The analysis of the preparations and their photographic documentation were 
performed using an Olympus BX41 microscope with a digital camera (Olympus DP12) 
and standard morphometric program (NIS- Elements Advanced Research software of 
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Nikon) installed on a computer. Ten randomly selected islets in each section were chosen, 
at a magnification 200x (20x the lens and 10x the eyepiece) for further morphometric 
analysis. The intensity of immunohistochemical reactions for each antibody was analyzed. 
Intensity of immunohistochemical reaction was measured by using 0 to 256 grey scale 
level, where a completely black pixel got a value of 0, whereas one with a value of 256 is 
completely white or bright. 
 
Ethical issues 
Study assumptions, aim, schedule and mode of animal treatment were approved by 
the Senate Committee for Supervision of Experiments on Humans and Animals, Medical 
University of Bialystok. 
 
Statistical analysis  
The analysis was performed using the StatisticaVersion 10.0 program. Results are 
expressed as means ± SD. The corresponding mean values were computed automatically; 
significant differences were determined by Student’s t-test; p<0.05 was taken as the level 
of significance.  
 
Results 
Serum creatinine and urea levels in rats subjected to unilateral nephrectomy and 
partial decortication of the other kidney were significantly increased in experimental 
animals in comparison to the values of those parameters in control rats (Table 1). 
Table 1. Serum concentrations of creatinine and urea in control and uraemic rats (mg/dL). 
 Control Uremic p-value 
Creatinine (mg/dL) 0.52±0.052 0.72±0.12 <0.05 
Urea (mg/dL) 35.33±5.98 85.58±9.766 <0.05 
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Routine H+E staining tests have revealed differences in islet morphology between 
both groups. In uremic rats, the pancreatic isles have a larger surface area and a more 
irregular shape compared to rats with normal renal function (Fig. 1A and B). 
A representative image of CB1 negative control (Fig. 2). All negative controls were 
similar. In each case omission of the primary antibody in immunohistochemical staining 
resulted in a lack of reaction. 
A positive reaction to CB1 and CB2 receptors was observed in the majority of 
pancreatic islet cells of all tested rats. The intensity of immunoreaction and distribution of 
these receptors were different in particular groups of animals. 
In control rats, strong or very strong immunoreactivity against CB1 receptors was 
observed throughout the islets of Langerhans. In the pancreas of rats with renal 
insufficiency, the intensity of the CB1-positive reaction was significantly weaker 
compared to the control animals and the density of CB1 receptors was higher on islets 
circumference (Fig. 3A and B). 
The use of an anti-CB2 antibody resulted in a very weak or marginal reaction in the 
pancreas of control rats (Fig. 4A). The result of the CB2-positive reaction was significantly 
greater in the pancreas of uremic rats. Some cells in the central parts of uremic rats' 
pancreatic islets showed moderate or strong immunoreactivity against CB2 (Fig. 4B). 
Immunohistochemical tests showed a typical arrangement of insulin- and glucagon- 
producing cells in all the examined rats. Insulin-positive cells were observed over the 
entire surface of the pancreatic islets (Fig. 5A and B), while glucagon-containing cells 
occurred primarily on islets periphery (Fig. 6A and B). 
The intensity of the immunohistochemical reaction revealing insulin in uremic rats 
was attenuated compared to the control group (Fig. 5). 
The intensity of the glucagon revealing immunoreaction in pancreatic islet α cells 
of the control group was moderate. Significantly higher immunoreactivity and an increased 
number of glucagon-positive cells was observed in pancreatic islets of uremic rats (Fig. 6 
A and B). 
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Computer analysis confirmed visually observed changes in reaction intensity (Table 2). 
 
Table 2. Comparative analysis of intensity of immunohistochemical reaction for CB1, 
CB2, insulin, glucagon in pancreatic islets of control and uremic rats  
Group Intensity of immunohistochemical reaction 
in scale from 0 (black pixel) to 256 (white pixel) 
(The mean value ± standard deviation) 
CB1 CB2 Insulin Glucagon 
Control 53.9 ± 2.98 175.5 ± 1.46 86.3 ± 3.7 115.1 ± 1.57 
Uremia 104.2 ± 3.67* 116.7 ± 3.40* 116.1 ± 7.07* 75.2 ± 5.02* 
* p < 0.05 uremia vs control 
 
Discussion 
The relationship between insulin-secreting β cells and glucagon-secreting α cells, 
which work together to maintain glucose homeostasis, within the pancreatic islets is an 
area of extensive research. A novel component of energy regulation, endocannabinoids, 
has recently been identified within the endocrine part of the pancreas. 
Homeostatic disorders occurring in uremia, within a short period of time manifest 
themselves in the abnormal secretion of hormones and other biologically active 
substances. It is known that the endocannabinoid system is involved in the regulation of 
the energy management of the body since elements of this system occur in key peripheral 
tissues that control metabolism, i.e. liver, adipose tissue, muscles, and in the endocrine part 
of the pancreas [2, 23, 33]. Cannabinoid receptors CB1, CB2 are present in pancreatic islet 
cells and are involved in the regulation of hormones secreted by them [13, 22, 30]. 
The aim of this study was to investigate, for the first time, the distribution of CB1 
and CB2 cannabinoid receptors as well as insulin- and glucagon-secreting cells in the 
pancreas of uremic rats. 
The results obtained in the experiment indicate statistically significant differences 
in the examined parameters in uremic and control rats. 
In this experiment, the CB1 and CB2 receptors were found to be present in the rat 
pancreatic islets as well as the immunoreactivity of the CB2 receptor was significantly 
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lower than that of CB1. Likewise, other experimental studies conducted by Bermúdez-
Silva et al. also have demonstrated presence of CB1 and CB2 receptor immunoreactivity in 
endocrine pancreas of male Wistar rats [6]. 
Our study demonstrated diminished immunoreactivity of the CB1 receptor in 
uremic rats in comparison to controls. The CB1 receptor density was higher at the 
periphery of the pancreatic islets in the examined rats whereas the intensity of the 
immunohistochemical reaction against the CB2 receptor was significantly higher in single 
pancreatic islet cells in uremic rats. Considering that in the current literature there is lack 
of reports concerning evaluation of cannabinoid receptors in pancreas in uremia, the 
discussion is quite difficult. 
Several studies show that the effects of activation or blockade, as well as the 
distribution of cannabinoid receptors in humans and in rats, are very similar [5, 6, 7, 11, 
22]. Laychock et al. showed an increase in insulin secretion in isolated rat pancreatic islets 
after the administration of Δ-9-tetrahydrocannabinol [22]. Bermúdez-Silva et al. observed 
an increase in insulin as well as glucagon secretion in human pancreatic islets after the 
administration of a CB1 receptor agonist [7]. In contrast, CB2 receptor stimulation reduced 
insulin secretion [7]. Getty-Kaushik et al. found decreased insulin secretion in pancreatic 
islets of obese Zucker and Zucker Diabetic Fatty rats treated with a CB1 receptor antagonist 
[13].  
The decrease in the CB1 receptor immunoreactivity observed in the present study 
in the central part of the islets may indicate the induction of protective mechanisms in the 
pancreatic islets in chronic renal failure. Confirmation of this hypothesis may be found in 
studies conducted by Janiak et al. [17] as well as Kim et al.[19]. Janiak et al. used a CB1 
receptor antagonist and observed the preservation of pancreatic weight and β cell mass in 
obese Zucker rats [17]. Kim et al. found that the blockade or genetic deficiency in the CB1 
receptor increases the survival of β cells in mice following the administration of 
streptozotocin [19]. Other studies conducted by Lin et al.  demonstrated that blockade of 
CB1R by treatment with CB1R antagonist attenuates the left ventricular hypertrophy and 
Akt-mediated cardiac fibrosis in chronic kidney disease mouse model [24]. On the other 
hand, Bátkai et al. showed protective role of CB2 receptor activation in hepatic 
ischemia/reperfusion injury in mice [4]. Similar observations were made by Montecucco et 
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al. in hearts from a mouse model of ischemia/reperfusion [27]. It is known that chronic 
kidney disease leads to increase in number of different substances provoking cell damage 
and apoptosis therefore observed decrease in CB1 receptor and increase in CB2 
immunoreactivity may be one of the possible adaptation processes aimed at limiting 
pancreatic islet cell destruction.  
In the pancreas of uremic rats, lower intensity of the insulin-positive reaction as 
well as stronger immunoreactivity of glucagon-positive cells were observed. 
Hyperglucagonemia in chronic renal failure is a phenomenon that has been repeatedly 
mentioned in various reports [8, 9, 12, 31]. The results of studies conducted by Koppe et 
al. show defective insulin secretion caused by the direct action of urea on β cells [20]. On 
the other hand, insulin resistance which develops during chronic renal failure also has a 
profound effect on the function of endocrine cells in the pancreatic islets [10, 21, 32, 36]. 
Several reports published to date illustrate that CB1 receptor antagonists have an 
inhibitory effect on insulin secretion [7, 10, 13]. Considering the information presented 
above and the results of our own research, it can be assumed that there may be CB1 
blocking agents in chronic renal failure. However, changes observed in our study may be 
the result of a number of different mechanisms and it is difficult to explain them at this 
stage since the body of knowledge regarding this issue is limited.  
It can be concluded that uremia leads to disorders of the insulin, glucagon 
production and CB1, CB2 immunoreactivity in the pancreatic islets as well as larger 
surface area and a more irregular shape of pancreatic islets in uremic rats compared to rats 
with normal renal function. That suggests the involvement of cannabinoid receptors in the 
pathomechanism of carbohydrate metabolism disorders in chronic kidney disease. 
The results of our studies can contribute to a better understanding of the changes 
occurring in the endocrine part of the pancreas in uremia as well as inspire other scientists 
to conduct research involving this important issue. 
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LEGENDS FIGURE  
Figure 1. Photomicrographs of pancreatic islet of control rat (A), uremic rat (arrow head) 
(B) (original magnification ×200). H+E stain 
Figure 2. Representative image of negative control reaction. Lack of reaction after 
omission of the primary antibody in immunohistochemical procedure (original 
magnification ×200). 
Figure 3. Immunodetection of CB1 receptor in pancreatic islet of control rat (A), uremic 
rat (arrows) (B) (original magnification ×200) 
Figure 4. Immunodetection of CB2 receptor in pancreatic islet of control rat (A),  uremic 
rat (arrows) (B) (original magnification ×200) 
Figure 5. Immunodetection of insulin in pancreatic islet of control rat (A), uremic rat 
(arrows) (B) (original magnification ×200) 
Figure 6. Immunodetection of glucagon in pancreatic islets of control rat (A), uremic rat 
(arrows) (B) (original magnification x200) 






